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Abstract
Background: Dolutegravir (DTG)-based antiretroviral therapy (ART) is highly effective and well-tolerated in adults
and is rapidly being adopted globally. We describe the design of the ODYSSEY trial which evaluates the efficacy
and safety of DTG-based ART compared with standard-of-care in children and adolescents. The ODYSSEY trial
includes nested pharmacokinetic (PK) sub-studies which evaluated pragmatic World Health Organization (WHO)
weight-band-based DTG dosing and opened recruitment to children < 14 kg while dosing was in development.
Methods: ODYSSEY (Once-daily DTG based ART in Young people vS. Standard thErapY) is an open-label,
randomised, non-inferiority, basket trial comparing the efficacy and safety of DTG + 2 nucleos(t) ides (NRTIs) versus
standard-of-care (SOC) in HIV-infected children < 18 years starting first-line ART (ODYSSEY A) or switching to
second-line ART (ODYSSEY B). The primary endpoint is clinical or virological failure by 96 weeks.
(Continued on next page)
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Results: Between September 2016 and June 2018, 707 children weighing ≥14 kg were enrolled; including 311 ART-
naïve children and 396 children starting second-line. 47% of children were enrolled in Uganda, 21% Zimbabwe,
20% South Africa, 9% Thailand, 4% Europe. 362 (51%) participants were male; median age [range] at enrolment was
12.2 years [2.9–18.0]. 82 (12%) children weighed 14 to < 20 kg, 135 (19%) 20 to < 25 kg, 206 (29%) 25 to < 35 kg, 284
(40%) ≥35 kg. 128 (18%) had WHO stage 3 and 60 (8%) WHO stage 4 disease. Challenges encountered include: (i)
running the trial across high- to low-income countries with differing frequencies of standard-of-care viral load
monitoring; (ii) evaluating pragmatic DTG dosing in PK sub-studies alongside FDA- and EMA-approved dosing and
subsequently transitioning participants to new recommended doses; (iii) delays in dosing information for children
weighing 3 to < 14 kg and rapid recruitment of ART-naïve older/heavier children, which led to capping recruitment
of participants weighing ≥35 kg in ODYSSEY A and extending recruitment (above 700) to allow for ≥60 additional
children weighing between 3 to < 14 kg with associated PK; (iv) a safety alert associated with DTG use during
pregnancy, which required a review of the safety plan for adolescent girls.
Conclusions: By employing a basket design, to include ART-naïve and -experienced children, and nested PK sub-
studies, the ODYSSEY trial efficiently evaluates multiple scientific questions regarding dosing and effectiveness of
DTG-based ART in children.
Trial registration: NCT, NCT02259127, registered 7th October 2014; EUDRACT, 2014–002632-14, registered 18th
June 2014 (https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002632-14/ES); ISRCTN, ISRCTN91737921,
registered 4th October 2014.
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Background
World Health Organization (WHO) guidelines recom-
mend immediate ART for all adults and children living
with HIV [1]. Although there has been substantial recent
improvement in coverage of antiretroviral therapy
(ART), only half of children in need have access to ART,
with the majority (> 80%) living in Sub-Saharan Africa
[2, 3]. The most commonly used regimens for human
immunodeficiency virus (HIV)-infected children are triple
combination ART with a ritonavir boosted protease in-
hibitor (bPI) or a non-nucleoside reverse transcriptase in-
hibitor (NNRTI). However, virological suppression on
these regimens is worse compared to adults [4, 5], oral
formulations of boosted-lopinavir are very poorly tolerated
and there are concerns regarding pre-treatment resistance
to NNRTIs in vertically-infected children [6, 7]. In this
context, there is a need for alternative first- and second-
line regimens for children with formulations which are
well tolerated, easy for health workers to prescribe and for
care-givers to administer.
Dolutegravir (DTG) is a second-generation integrase
inhibitor with the advantage of once-daily dosing, a
good short-term safety profile, low pharmacokinetic
(PK) variability, few drug-to-drug interactions, rapid
and robust virological response, a distinct resistance
profile from raltegravir, a high genetic barrier to re-
sistance and high potency at a low milligram dose.
Following adult Phase II/III trials [8–12], the ODYS-
SEY trial aims to evaluate the efficacy and safety of
once-daily DTG-based ART compared with standard-
of-care (SOC) in children and adolescents (< 18 years)
starting first- or second-line ART in resource-limited
and well-resourced settings. We hypothesise that DTG
with 2 nucleos(t) ides reverse transcriptase inhibitors
(NRTIs) will be non-inferior to SOC in terms of efficacy
and superior in terms of toxicity profile. This paper de-
scribes the design of the ODYSSEY trial, which has
evolved over time to include nested PK sub-studies to
evaluate pragmatic WHO weight-band-based DTG dosing
and to open recruitment to children < 14 kg while dosing
was still in development.
Changing licensing and guidelines for Dolutegravir
When ODYSSEY opened in September 2016, the US
Food and Drug Administration (FDA) and the European
Medicines Agency (EMA) had licensed the adult DTG
dose (50 mg film coated tablet (FCT)) in adolescents
weighing ≥40 kg and the FDA had licensed DTG 35mg
FCT in children weighing between 30 and 40 kg. Add-
itionally, data from the ongoing IMPAACT P1093, a
paediatric Phase II/III dose-finding study, supported
using DTG 25mg FCT in children over 6 years weighing
between 20 and 30 kg [13]. In February 2017, the EMA
reduced the weight and age limits for children down to
≥15 kg and ≥ 6 years.
Supported by further emerging efficacy data in adults
[14] and the low cost of DTG, a number of countries
had procured DTG formulations for adults by the end of
2017 [4]. In May 2018, data from an unplanned analysis
of a National Institutes of Health (NIH)-funded observa-
tional surveillance study of pregnancies in Botswana
(TSEPAMO) suggested an increased risk of neural tube
Moore et al. BMC Infectious Diseases            (2021) 21:5 Page 2 of 14
defects (NTD) in infants born to women who became
pregnant while taking DTG (data from August 2014
through to March 2019 showed 5 cases of NTD in 1683
infants (0.3%), which compares to a risk of ~ 0.1% in in-
fants born to women on non-DTG based regimens)
[15–17]. WHO issued a statement advising of a poten-
tial DTG safety signal [18]. Despite this, in July 2018,
in response to efficacy data and the increasing levels
of pre-treatment ART resistance documented in low-
and middle-income countries (LMICs), WHO updated
its recommendations to include DTG-based ART as a
preferred first-line regimen for HIV-positive individ-
uals ≥6 years and ≥ 15 kg (with alternative options for
females of child-bearing age not using effective
contraception) [19]. Updated data from the TSEP
AMO study suggested that any increased risk of NTDs
is lower than originally reported [17, 20]. President’s
Emergency Plan for AIDS Relief (PEPFAR) and other
partners continue to encourage responsible rollout
[21]. In their 2020 report, the Clinton Health Access
Initiative (CHAI) predicted that DTG-based first-line
regimens would have a 93% market share in LMICs by
2024 [21].
Paediatric DTG formulations lag behind the adult
formulation significantly. Although paediatric film-
coated formulations (10 mg FCT, 25 mg FCT) were
approved by stringent regulatory authorities in the US
and Europe in 2016–2017, they are still not available
outside high resource countries. Paediatric dispersible
tablets, having only been recently approved in the US,
are not yet available in countries.
Methods
Study design, number of children, randomisation and
follow-up
ODYSSEY is an open-label, multi-centre, randomised,
non-inferiority, Phase II/III, 96-week basket trial, powered
to evaluate DTG-based ART in 2 cohorts: ART-naïve chil-
dren (ODYSSEY A) and children starting second-line
(ODYSSEY B). Children (< 18 years) were recruited at sites
located in Uganda, South Africa, Zimbabwe, Thailand,
Portugal, Germany, Spain and the United Kingdom. A
basket design allows for enrolment to occur to two
(or more) cohorts simultaneously at the same clinical
sites, thereby improving efficiency and minimizing
time and costs [22]. At trial design we planned to
randomise 700 children (310 in ODYSSEY A and 390
in ODYSSEY B) 1:1 to receive 2 NRTIs with DTG
(DTG arm) or SOC (bPI-, NNRTI- or non-DTG
INSTI-based ART; SOC arm) (Fig. 1). Randomisation
of children was stratified by ODYSSEY A/ODYSSEY
B, routine availability at site of resistance tests for
children failing treatment, intended SOC (bPI/non-bPI
ART) and intended NRTI backbone (both specified
prior to randomisation). The randomisation list was
prepared by the trial statistician using random per-
muted blocks and securely incorporated within the
trial database. Randomisation of study participants
was done via a web service accessed by site clinician
or one of the coordinating trials units. Allocation was
concealed until randomisation occurred after which
allocation was open—i.e. clinicians and carers were
aware of group assignment.
Fig. 1 Trial Schema. Note: 85 additional children weighing 3 to < 14 kg were randomised to DTG versus SOC and will be followed up for 96
weeks. Abbreviations: ART = Antiretroviral Therapy; NRTI=Nucleos(t) ide reverse transcriptase inhibitors; bPI = boosted-Protease Inhibitors; NNRTI=
Non-nucleoside reverse-transcriptase inhibitors; INSTI=Integrase Inhibitors
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As a result of delays in dosing information for children
< 14 kg, the trial was modified before recruitment closed
to allow for the inclusion of ≥60 additional children
weighing 3 to < 14 kg at enrolment (including a mini-
mum of 20 children in each of the three lower weight-
bands: 3 to < 6 kg, 6 to < 10 kg, 10 to < 14 kg) with par-
ticipation in a PK sub-study for those randomised to the
DTG arm. Minimum targets of 20 per weight-band were
based on requiring ≥8 evaluable PK curves per weight
band in the DTG arm and clinical opinion regarding
numbers required < 14 kg to assess alongside the chil-
dren ≥14 kg. Total enrolment was increased to allow for
these additional children. Follow-up for the main trial
population continued until the last ≥14 kg child re-
cruited completed 96 weeks; each of the additional chil-
dren < 14 kg is being followed-up for 96 weeks from
randomisation. Including these extra children takes ad-
vantage of the opportunity ODYSSEY offers for a rando-
mised comparison of DTG versus SOC in these
younger/lighter children. Concurrent recruitment of
children 3 to < 14 kg alongside the children weighing
≥14 kg was allowed for with randomisation stratified by
< 14 kg and ≥ 14 kg to protect the main trial population ≥
14 kg where randomisation was preserved. Randomisa-
tion of children < 14 kg was further stratified by weight-
band (3 to < 6 kg, 6 to < 10 kg, 10 to < 14 kg) and ODYS-
SEY A/ODYSSEY B. Our design was planned to be ro-
bust if any/all of the lower weight-bands had to be
dropped from the randomised comparison. Sub-study
data were reviewed in children < 14 kg by the Independ-
ent Data Monitoring Committee (IDMC) (safety, efficacy
and PK data) and by the Trial Steering Committee, ViiV
Healthcare and the Trial Management Group (safety
and PK data in DTG arm); had DTG been discontinued
in any weight-band for safety concerns, PK concentra-
tion levels or lack of efficacy, we would have been able
to drop children recruited in the respective weight-band
(DTG and SOC participants) from our treatment com-
parisons. We are also able to analyse and report data on
children enrolled weighing ≥14 kg while data are still ac-
cumulating in the children < 14 kg.
Study population
Eligibility criteria for ODYSSEY have changed over time
mostly to expand eligibility to younger/lighter children
(Table 1). In the initial ODYSSEY protocol, children had
to be over 6 years and weighing ≥20 kg to be eligible.
Throughout the trial, eligibility in both arms was contin-
gent on a confirmed DTG dose being available for a
given age/weight-band (or eligibility for a PK sub-study).
Delays in dosing information for children< 14 kg and fast
enrolment of ART-naïve children ≥35 kg led to the deci-
sion to cap recruitment of ART naïve children ≥35 kg in
July 2017. When we stopped screening children ≥35 kg
for ODYSSEY A, 100/172 enrolled in A were ≥ 35 kg,
with the majority (94/100) aged 12 years or over. Al-
though no cap was included in the protocol, the Trial
Management Group and oversight committees consid-
ered it important to increase numbers < 35 kg and to
keep trial places for younger children.
Treatment of patients
NRTI backbone and SOC third-agents are prescribed ac-
cording to national guidelines. Planned treatment was
recorded prior to randomisation which was stratified
(for children ≥14 kg) by whether or not bPI would be of-
fered as SOC and by NRTI backbone, to ensure treat-
ment groups were balanced for these factors. In
countries where drug resistance tests were routinely per-
formed, it was recommended that at least one active
NRTI was chosen. In countries where drug resistance
tests were not routinely performed, it was recommended
at least one NRTI was chosen with presumed preserved
activity based on treatment history.
DTG dose by protocol version has changed over time
(Table 2) and has been driven by new licensing informa-
tion and emerging data from IMPAACT P1093 [24] and
ODYSSEY PK sub-studies (see below).
Primary and secondary endpoints
The primary endpoint for the trial is virological or clin-
ical failure by 96 weeks, which is defined as the first oc-
currence of any of the following: 1) insufficient
virological response, 2) virological failure (two consecu-
tive viral load measures ≥400 c/ml with the first at/after
week 36), 3) new or recurrent AIDS defining event
(WHO 4) or severe WHO 3 event, adjudicated by an in-
dependent blinded endpoint review committee or 4) all-
cause death. The primary comparison is DTG vs SOC in
the combined trial population (first-line and second-line
children combined); subpopulation analyses (ODYSSEY
A and ODYSSEY B) are key secondary comparisons.
The components of the primary composite endpoint
(virological failure and clinical failure) are included as
secondary endpoints in addition to other key outcomes
(Table 3).
Sample size calculations
A non-inferiority margin of 10–12% was chosen, in ac-
cordance with previous HIV treatment trials [25, 26].
Assuming a failure rate of 18% overall (first-line and
second-line children combined) in the DTG arm and
SOC arm by 96 weeks and allowing for 10% loss to
follow-up, 700 children provide 90% power to exclude
(at two-sided 5% significance level) a difference of more
than 10% in the primary outcome between the two arms.
Enrolling 310 first-line ART and 390 s-line ART children
provide 80% power to exclude a difference of more than
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12% between the DTG and SOC arms in both subgroups
separately, assuming a failure rate of 15% in ART-naïve
(based on previous trials [27]) and 20% in ART-
experienced children with 10% loss to follow-up.
Sub-studies
PK sub-studies
Weight-band PK sub-studies were introduced in Proto-
col version 3.0 (March 2017) with the aim of simplifying
doses (using WHO weight-bands with no age restric-
tions) and using DTG formulations planned for manu-
facturing by generic companies.
In the first sub-study, PK and safety data were col-
lected on 33 children weighing 14 to < 25 kg on DTG
25mg FCT (Table 4). Exposures were low compared to
reference data in adults [28].
In the second sub-study, 28 children weighing 25 to <
40 kg had PK on their initial dose (25 mg or 35 mg
FCT); they then switched to the adult 50 mg FCT dose
and underwent further PK and safety monitoring (Table
4). Based on the results of this sub-study [23] and fol-
lowing ethics approval, all children in the main trial
weighing ≥25 kg moved to the adult 50 mg FCT dose.
Based on the results of the first two sub-studies, chil-
dren weighing 14 to < 20 kg were changed to DTG 25
mg dispersible tablets (5x5mg DT which have higher
bioavailability than FCTs), and children weighing 20 to
< 25mg were changed to DTG 30mg DT (6x5mg DT)
Table 1 Participant Inclusion and Exclusion Criteria from Protocol Version 4.0 onwards
Inclusion Criteria:
All • Children ≥28 days and < 18 years weighing ≥3 kg with confirmed HIV-1 infectiona
• Parents/carers and children, where applicable, give informed written consent
• Girls who have reached menses must have a negative pregnancy test at screening and randomisation and be
willing to adhere to effective methods of contraception if sexually active
• Children with co-infections who need to start antiretroviral therapy can be enrolled according to local/national
guidelines
• Parents/carers and children, where applicable, willing to adhere to a minimum of 96 weeks’ follow-up
ODYSSEY A (First-line) only • Planning to start first-line antiretroviral therapy
ODYSSEY B (Second-line)
only
• Planning to start second-line antiretroviral therapy defined as either: (i) switch of at least 2 antiretroviral therapy
drugs due to treatment failure; or (ii) switch of only the third agent due to treatment failure where drug sensitivity
tests show no mutations conferring nucleos(t) ide reverse transcriptase inhibitors resistance
• Treated with only one previous antiretroviral therapy regimen. Single drug substitutions for toxicity, simplification,
changes in national guidelines or drug availability are allowed
• At least one nucleos(t) ide reverse transcriptase inhibitor with predicted preserved activity available for a
background regimen
• In settings where resistance tests are routinely available, at least one active nucleos(t) ide reverse transcriptase
inhibitor from TDF/TAF, ABC or ZDV should have preserved activity based on cumulative results of resistance tests
• In settings where resistance tests are not routinely available, children who are due to switch according to national
guidelines should have at least one new nucleos(t) ide reverse transcriptase inhibitor predicted to be available from
TDF/TAF, ABC or ZDV
• Viral load ≥500 c/ml at screening visit or within 4 weeks prior to screening‡
Exclusion Criteria:
All • History or presence of known allergy or contraindications to dolutegravir
• History or presence of known allergy or contraindications to proposed available nucleos(t) ide reverse transcriptase
inhibitor backbone or proposed available standard-of-care third agent.
• Alanine aminotransferase (ALT) ≥5 times the upper limit of normal (ULN), OR ALT ≥3xULN and bilirubin ≥2xULN
• Patients with severe hepatic impairment or unstable liver disease (as defined by the presence of ascites,
encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), known
biliary abnormalities (with the exception of Gilbert’s syndrome or asymptomatic gallstones)
• Anticipated need for Hepatitis C virus therapy during the study
• Pregnancy or breastfeeding
• Evidence of lack of susceptibility to integrase inhibitors or more than a 2-week exposure to antiretrovirals of this class
a Recruitment of ART naive children ≥35 kg was capped in Jul 2017. Recruitment opened in children ≥6 years and < 18 years weighing ≥20 kg (Protocol version
2.0). Protocol version 3.0 included recruitment of children ≥14 kg (with no age restriction) with a lead-in PK sub-study for children weighing 14 to < 20 kg
(children weighing 14-15 kg had to be willing to enter the lead-in PK sub-study to enrol in the trial). Protocol version 4.0 onwards allows allowed for the
recruitment of children ≥3 kg and ≥ 28 days, children weighing 3 to < 14 kg had to be willing to participate in a lead-in PK sub-study to enter the trial. Throughout
the trial eligibility was based in both arms on availability of DTG dose given age/weight-band. ‡ Protocol version 3.0 onwards (viral load ≥1000 c/ml in protocol
version 2.0)
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or DTG 50mg FCT, with further PK and safety monitor-
ing. Data on children weighing 20 to < 25mg taking the
adult DTG 50mg FCT also demonstrated appropriate
PK profiles [29].
Following review of ODYSSEY PK sub-study results by
the Pediatric Antiretroviral Working Group (PAWG) of
the WHO, WHO paediatric dosing guidelines have been
updated to allow children 20 to < 40 kg to receive the
adult 50 mg FCT dose [19].
Recruitment of children weighing 3 to < 14 kg was ini-
tiated under protocol version 4.0 and children rando-
mised to DTG completed PK assessments [30].
A TB-PK sub-study with a within-child cross-over design
is also evaluating the PK of DTG co-administered with ri-
fampicin in HIV/tuberculosis (TB) co-infected children.
Children on DTG diagnosed with TB start on rifampicin
(RIF) and receive BID DTG (doubled daily dose) for the
duration of TB treatment, and 2 weeks following. The first
PK is undertaken at the end of TB treatment; followed by a
second PK on QD DTG (once daily) ≥4 weeks after RIF is
stopped, to allow for a wash-out period [31].
An immunology/virology sub-study will explore
mechanisms of CD4 reconstitution, immune activation,
HIV reservoir and low-level viral replication in the DTG
and SOC arms.
A qualitative sub-study is investigating how best to sup-
port young people to maintain optimal adherence to
second-line treatment, using interviews and focus groups
with a small proportion of participants and carers in ODYS-
SEY B [32]. Young people and caregivers’ understanding of
the DTG pregnancy safety alert have also been explored.
A folate and vitamin B12 sub-study at Ugandan sites
was added in protocol v5.0 following the concerns raised
around an increased risk of NTDs in babies born to
mothers on DTG at conception [18]. Red cell folate and
vitamin B12 levels will be assayed in samples prospect-
ively collected at week 96 or later and compared be-
tween trial arms; change in plasma folate levels between
week 4 and baseline (using routinely collected stored
samples) will also be compared between arms.
In addition to the sub-studies, Youth Trial Boards in
Uganda, Zimbabwe, South Africa and the UK have been
developed alongside ODYSSEY to allow for meaningful en-
gagement and participation of adolescent patient represen-
tatives in paediatric clinical trials. To date, they have had
input into patient information sheets, have developed tools
for explaining the risks of DTG in pregnancy to young
people, and have participated in the development of a
WHO toolkit and WHO webinars on youth participation
in research.








ODYSSEY v2.0a ODYSSEY v3.0 ODYSSEY v4.0 ODYSSEY v5.0/v6.0
(Sep 2016
onwards)
(Mar 2017 onwards) (May 2018 onwards) (May 2019/Feb 2020
onwards)
3 to < 6 kg – – – –
6 to < 10
kg
– – – –
10 to < 14
kg
– – – –













25 mg FCT 25 mg FCT 25 mg FCT→ 30mg DT or 50
mg FCTf
50 mg FCT






25 mg FCT 25 mg FCT→ 50 mg
FCTe
25 mg FCT→ 50mg FCTe 50 mg FCT










35 mg FCT 35 mg FCT→ 50 mg
FCTe
35 mg FCT→ 50mg FCTe 50 mg FCT










35 mg FCT 35 mg FCT→ 50 mg
FCTe









50 mg FCT 50 mg FCT 50 mg FCT 50 mg FCT
Abbreviations: FCT Film-coated tablets, DT Dispersible tablets, v Version
a Approval in ≥12 years in Aug 2013, restriction removed Jun 2016
b Approval in ≥12 years in Jan 2014, ≥6 years in Feb 2017
c 20 mg FCT approved by EMA in children weighing 15 to < 20 kg only
d From May 2017, ≥6 years, in children weighing 15 to < 20 kg only
e From 1st of Apr 2018, after ethics notification, sites following protocol version 3.0 and above were recommended to increase the DTG dose of children 25 to <
40 kg to 50 mg FCT QD at their next scheduled study visit based on the results of the weight-band pharmacokinetic sub-study [23]
f Protocol version 4.0 also allowed for the adjustment of weight-band dose based on findings from the ongoing weight-band pharmacokinetic sub-study with
ethics notification
g Protocol version 1.0 was not used
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Study procedures
All participants are seen at screening, enrolment, week
4, 12 and every 12 weeks to the end of follow-up. Every
visit includes a clinical assessment including height,
weight (and adjustment of drug doses accordingly),
change in HIV disease stage, clinical events, adverse
events and an adherence assessment (Table 5). In proto-
col version 3.0, questionnaires assessing mood and sleep
symptoms were added. CD4, CD8, biochemistry and
haematology laboratory tests are done at baseline, 4
weeks, 24 weeks and then 24-weekly, with lipids and glu-
cose measured at baseline and 48-weekly. At sites where
viral load is routinely measured every 12–16 weeks, real-
time viral loads are measured at screening, week 4, 12,
24 and then every 12 weeks. At other sites, a real-time
viral load is measured at screening (unless one is avail-
able from the last 4 weeks) to confirm eligibility in
ODYSSEY B participants; otherwise viral loads are done
according to local routine practice, and plasma samples
stored at the above time-points for retrospective testing.
Retrospective viral load testing is done in batches, and
results are not used for patient management; this en-
sures generalisability of the trial results to LMIC settings
where viral load is measured only 6 or 12-monthly ac-
cording to WHO [33] and national guidelines. All viral
load results are reviewed during the trial by the IDMC
and we aim to have results of batched testing up-to-date
for each IDMC review.
Study organisation, governance and ethics
The sponsor of the trial is the Paediatric European Net-
work for Treatment of AIDS (PENTA) Foundation
(https://penta-id.org/). Management of the trial is dele-
gated to the clinical trials units: Medical Research Coun-
cil Clinical Trials Unit at UCL (MRC CTU at UCL),
French National Institute for Health and Medical
Research-French National Agency for Research on AIDS
Table 3 Primary and secondary outcome measures in odyssey
Primary Efficacy Outcome
Difference in proportion with clinical or virological failure by 96 weeks,
defined as the first occurrence of any of the following components:
1. Insufficient virological response defined as <1 log10 drop at week 24
(or viral load ≥50c/mL at week 24 in a participant with viral load <
500c/mL at baseline) and switch to second/third line antiretroviral
therapy for treatment failure
2. Virological failure (defined as a viral load of greater than or equal to
400 copies/mL at or after week 36 confirmed by the next visit)
3. New or recurrent AIDS defining event (WHO 4) or severe WHO 3
event, confirmed by the Endpoint Review Committee (see Appendix)
4. All-cause death
Secondary efficacy outcomes
Difference in proportion with clinical or virological failure (as defined
above) by 48 weeks
Time to any new or recurrent AIDS defining event (WHO 4) or severe
WHO 3 events, confirmed by the Endpoint Review Committee
Proportion of children with Viral Load < 50 c/ml at 48 and 96 weeks
Proportion of children with Viral Load < 400 c/ml at 48 and 96 weeks
Rate of HIV-associated events (WHO 4 and severe WHO 3) and death
over 96 weeks
Change in CD4 count and percentage and CD4/CD8 ratio from baseline
to weeks 48 and 96
Proportion developing new resistance mutations
Secondary safety outcomes
Change in total cholesterol, triglycerides and lipid fractions (high-density
lipoproteins, low-density lipoproteins) from baseline to weeks 48 and 96
(change in total cholesterol from baseline to week 96 will be used to
formally assess superiority of dolutegravir-based regimen vs. standard-of-
care)
Incidence of serious adverse events
Incidence of new clinical and laboratory grade 3 and 4 adverse events





Table 4 Dolutegravir dosing in odyssey pk sub-study participants by protocol version
WHO weight-band Initiated under Protocol v3.0 Initiated under Protocol v4.0
3 to < 6 kg – Single PK Curve on 5mg or 10 mg DTa
6 to < 10 kg – Single PK Curve on 15 mg DT
10 to < 14 kg – Single PK Curve on 20 mg DT
14 to < 20 kg Single PK Curve on 25 mg FCT Single PK Curve on 25 mg DTb
20 to <25 kg Single PK Curve on 25 mg FCT Single PK Curve on 30 mg DT or 50 mg FCTb
25 to < 30 kg Cross-over PK with one curve on 25mg FCT and second curve on 50 mg FCT –
30 to < 35 kg Cross-over PK with one curve on 35mg FCT and second curve on 50 mg FCT –
35 to < 40 kg Cross-over PK with one curve on 35mg FCT and second curve on 50 mg FCT –
≥40 kg – –
Abbreviations: FCT Film-coated tablets, DT Dispersible tablets, v Version, PK Pharmacokinetic
aDTG dose for infants 3- < 6 kg is dependent on age initially. Infants < 6 months of age receive DTG 5mg QD while infants ≥6months of age receive DTG 10mg
QD, both as dispersible tablets
bPreference given to enrolment of children who completed PK on 25mg FCT initiated under protocol version 3.0
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and Viral Hepatitis (INSERM-ANRS) and PHPT-UMI
174 in Thailand. The trial was submitted for approval by
Research Ethics Committees/Institutional Review Boards
and by all required regulatory authorities in each of the
participating countries.
Statistical analysis plan
The primary analysis will take place after the last partici-
pant recruited weighing ≥14 kg has completed 96 weeks
and all children ≥14 kg have had a study closeout visit
and will only include data in children recruited weighing
≥14 kg. The cumulative probability of clinical or viro-
logical failure by week 96 will be compared in the DTG
and SOC arms, using the intention-to-treat population,
estimated by the Kaplan-Meier Method adjusting for
stratification factors. If the upper limit of the confidence
interval for the difference between arms is < 10%, DTG-
based ART will be considered non-inferior to SOC.
The primary endpoint includes confirmed HIV RNA ≥
400 c/ml at or after 36 weeks. Since sites with frequent
real-time viral load testing are likely to confirm failure
more quickly than sites testing 6-monthly or annually, to
ensure consistency for this endpoint the date of next
scheduled visit following the first HIV RNA ≥400 (using
schedule from randomisation) will be used for time to
first confirmed viral load measurement ≥400c/ml (pri-
mary endpoint failure date), rather than the date of the
confirmatory measure. Sensitivity analyses will include
defining failure at first of two consecutive HIV RNA ≥
400 c/ml at or after 36 weeks.
A small number of participants were randomised with
minor ineligibility reasons and were retained in the trial.
A secondary analysis will be done in the per protocol
population excluding participants who did not meet the
eligibility criteria and censoring follow-up at any change
to the third agent (i.e. a change in either an INSTI, a PI,
Table 5 Clinical assessments undertaken and frequency of testing
Clinical Assessment Frequency of Assessment
History and clinical assessment including height, weight (and adjustment
of drug doses accordingly) and mid upper arm circumference, change in
HIV disease stage, clinical events and presence of adverse events.
Every study visit
Tanner scale (children aged 8 or over) Baseline, then every 24 weeks and at the end of study visit
Lipodystrophy assessment including at selected sites bioelectrical
impedance analysis.
Baseline, then every 48 weeks and at the end of study visit
HIV-1 RNA viral load Every study visit as per local practice. In ODYSSEY B viral load must be
measured at screening unless the viral load has been done within 4 weeks
prior to screening. Stored plasma samples will be used to examined viral
load for study visits where viral load is not routinely done.
T cell lymphocyte subsets including CD4 and CD8 percentage and
absolute, total lymphocyte count
Baseline, 4, 12, 24, then 24-weekly until week 96 and at the end of study
visit
Biochemistry including creatinine, bilirubin, alanine aminotransferase
(ALT), and optionally aspartate aminotransferase (AST)
Baseline, 4, 24, then 24-weekly until week 96 and at the end of study visit
Haematology including haemoglobin, mean corpuscular volume (MCV),
white blood cell count, lymphocytes, neutrophils, and platelets
Baseline, 4, 24, then 24-weekly until week 96 and at the end of study visit
Lipids/glucose including fasted triglycerides, cholesterol (total, high-
density lipoproteins, low-density lipoproteins), and glucose
Baseline, 48, 96 weeks, then every 48 weeks and at the end of study visit
Bone profile including calcium, phosphate, alkaline phosphatase Optional for all sites at baseline, 48, 96 weeks, then every 48 weeks and at
the end of study visit
Urine dipstick for protein and glucose Baseline, 48, 96 weeks then every 48 weeks and at the end of study visit
Quality of Life questionnaire Baseline, 12, 24, 48, 96 weeks then every 48 weeks and at the end of study
visit
Pregnancy test (for all females of childbearing potential) This was originally at baseline and then every 24 weeks but following the
pregnancy alert in DTG in May 2018 this was updated to every study visit
(see Section entitled ‘Pregnancy Alert’)
Plasma storage for retrospective HIV-1 RNA viral load, resistance testing
where not routinely available locally and sub-study assays
Every visit
Peripheral blood mononuclear cell storage at selected sites for
immunology/virology sub-study
At selected sites for baseline, 12, 48, and 96 weeks
Adherence questionnaire Every visit
Acceptability, sleep & mood questionnairea Baseline, 4, 12, 24, 48, 72, 96 weeks, then every 24 weeks and at the end of
study visit. Also acceptability should be completed if treatment failure has
occurred or the antiretroviral therapy regimen changed.
a Sleep and mood questions including from protocol version 3.0 onwards
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or an NNRTI, including adding an additional third agent
or stopping treatment for > 31 days) for toxicity, failure
or pregnancy/planned pregnancy.
Participants with VL < 50 (or < 400) c/ml at 48 and 96
weeks will be compared between arms based on (i) crude
proportions and (ii) using the FDA snapshot algorithm.
Change in total cholesterol, triglycerides and lipid frac-
tions (LDL, HDL) from baseline to weeks 48 and 96 will
be analysed using analysis of covariance to compare the
change in mean level between the two arms, adjusting
for baseline value and stratification factors. Other end-
points will be assessed using appropriate statistical
methods.
There will be a secondary analysis of primary and sec-
ondary endpoints in children recruited weighing < 14 kg
when this group has completed 96 weeks follow-up.
Bayesian estimation will be used to report the primary
endpoint, incorporating evidence obtained from partici-
pants enrolled ≥14 kg as a prior distribution. Clinical
opinion has been elicited on the relative weight to allo-
cate to the prior distribution [34]. The Bayesian analysis
will be reported alongside frequentist analyses of the <
14 kg participants and of the whole trial population (<
and ≥ 14 kg).
Results
Challenges in study implementation- changing landscape
of DTG dosing
As described above, eligibility to ODYSSEY has ex-
panded since the trial began to include younger/lighter
children and DTG doses have been tested and modified
within weight-bands, with protocol amendments, based
on the PK sub-study results [23, 29] and with IDMC,
TSC and ethics approval. This has increased the com-
plexity of the trial for trial teams, particularly at PK sites.
Drug supply management has also been challenging, to
ensure correct DTG formulations are available at clinical
centres in a timely manner.
The impact of using different DTG dosing within the
same weight-band on the main trial comparison has
been considered. We have taken the view that the trial
will be a pragmatic comparison of DTG vs SOC for clin-
ical or virological failure, and consider that it is more
valuable to collect follow-up information on the doses
likely to be licensed and used, particularly in low-
resource settings.
Challenges in study implementation- pregnancy alert
The following measures were in place for girls of child-
bearing age prior to the DTG safety alert reporting a
possible association between becoming pregnant on
DTG and an increased risk of neural tube defect in the
infant [15]:
 Eligibility contingent on negative pregnancy test and
adherence to effective methods of contraception
(Table 1)
 A pregnancy test every 24 weeks
 Pregnancies in trial participants reported, and
outcomes followed-up
 Clinician discretion with respect to continuing DTG
during pregnancy, with advice to consider
alternative ART.
Following the safety alert, the trial team took the fol-
lowing actions:
 Participants were notified of this potential safety
risk, prioritising those ≥15 years.
 Patient information sheets and consent forms were
updated
 Availability of contraception and contraceptive
counselling at each site was reviewed, and
strengthened if necessary. Case report forms were
revised to collect information about use of
contraceptives.
 Participants in the DTG arm who have a positive
pregnancy test within 8 weeks of their last menstrual
period or who wish to become pregnant are now
advised to switch to a non-DTG ART regimen in
consultation with their clinician.
 The frequency of pregnancy testing for girls of
childbearing age was increased to every (12-weekly)
follow-up visit.
 Collection of data on use of folate supplements
(advised during pregnancy) was strengthened.
 Youth Trial Board members created adolescent-
friendly information on the safety alert, which can
be provided to trial participants.
Post-trial access to DTG
Adult DTG (50 mg FCT) has been registered in all par-
ticipating countries and is widely available in Europe
and Africa. DTG DT formulations are unlikely to be
available by the end of the trial. Protocol v6.0 includes
extended observational follow-up for children in Africa
and Thailand in both trial arms for a further 3 years;
children on DTG at the end of the trial who continue in
follow-up will be provided with DTG DT and (in
Thailand) 50 mg FCT through ViiV Healthcare as
necessary.
Current status of the trial
Between 20th September 2016 and 22nd June 2018,
707 children ≥14 kg were enrolled, including 311
ART-naïve children and 396 children starting second-
line; enrolment was then closed to children ≥14 kg.
Table 6 describes the baseline characteristics of
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Table 6 Baseline characteristics of odyssey participants ≥14 kg at randomisation
ODYSSEY A ODYSSEY B Total
(First-line) (Second-line)
Participants randomised ≥14 kg 311 396 707
Country/region
Europe 18 (6%) 7 (2%) 25 (4%)
South Africa 76 (24%) 67 (17%) 143 (20%)
Thailand 50 (16%) 11 (3%) 61 (9%)
Uganda 99 (32%) 232 (59%) 331 (47%)
Zimbabwe 68 (22%) 79 (20%) 147 (21%)
Sex
Male 147 (47%) 215 (54%) 362 (51%)
Female 164 (53%) 181 (46%) 345 (49%)
Age, years
2 to < 6 12 (4%) 14 (4%) 26 (4%)
6 to < 12 155 (50%) 161 (41%) 316 (45%)
12 to < 18 144 (46%) 221 (56%) 365 (52%)
Weight, kg
14 to < 20 38 (12%) 44 (11%) 82 (12%)
20 to < 25 62 (20%) 73 (18%) 135 (19%)
25 to < 30 58 (19%) 59 (15%) 117 (17%)
30 to < 35 33 (11%) 56 (14%) 89 (13%)
35 to < 40 kg 22 (7%) 39 (10%) 61 (9%)
≥40 kg 98 (31%) 125 (32%) 223 (31%)
BMI-for-Age Z-Scorea
<−3 12 (4%) 21 (5%) 33 (5%)
−3 to < −2 24 (8%) 24 (6%) 48 (7%)
−2 to < 0 178 (57%) 257 (65%) 435 (62%)
≥0 97 (31%) 94 (24%) 191 (27%)
Mode of infection
Mother-to-child 240 (77%) 365 (92%) 605 (86%)
Blood product 1 (<1%) 2 (1%) 3 (<1%)
Sexual contact 36 (12%) 3 (1%) 39 (6%)
Unknown 32 (10%) 26 (7%) 58 (8%)
Otherd 2 (1%) 0 (0%) 2 (<1%)
CD4, cells/mm3b
< 100 56 (18%) 54 (14%) 110 (16%)
100 to < 200 20 (6%) 29 (7%) 49 (7%)
200 to < 500 103 (33%) 128 (32%) 231 (33%)
500 to < 1000 99 (32%) 130 (33%) 229 (32%)
≥1000 33 (11%) 55 (14%) 88 (13%)
CD4, %
< 15 110 (35%) 119 (30%) 229 (32%)
15 to < 25 100 (32%) 104 (26%) 204 (29%)
≥25 101 (32%) 173 (44%) 274 (39%)
Median CD4 (IQR), cells/mm3b 436 (210–660) 482 (243–752) 459 (228–704)
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children enrolled ≥14 kg: 621 (88%) have been en-
rolled in Africa; median (range) age was 12.2 [2.9–
18.0]; 128 (18%) had WHO stage 3 and 60 (8%)
WHO stage 4 disease; the majority were vertically in-
fected. SOC is primarily efavirenz-based for ART-
naïve children and lopinavir/ritonavir-based for ART-
experienced children with abacavir+lamivudine or
tenofovir+lamivudine/emtricitabine. Children recruited
≥14 kg all reached 96 weeks follow-up by end April
2020, with primary results expected by early 2021.
Recruitment of children weighing 3 to < 14 kg started
5th July 2018 and completed 26th August 2019; 85
children were recruited, all in African sites, including
23 weighing 3 to < 6 kg, 39 weighing 6 to < 10 kg and
23 weighing 10 to < 14 kg at enrolment.
Discussions
The ODYSSEY trial is an ambitious trial which has
recruited HIV-infected children across 29 sites in 8
countries to evaluate DTG-based ART versus SOC.
Recruitment of ≥700 children was completed ahead
of target and an additional 85 children < 14 kg were
recruited over 13 months. ODYSSEY employs a bas-
ket design to include ART-naïve and ART-
experienced children, and, although the primary
comparison will be in all children, the trial is pow-
ered to evaluate non-inferiority of DTG vs SOC in
both sub-groups. To ensure relevance of findings
across sub-Saharan Africa, where most HIV-infected
children live, national guidelines are adhered to for
real-time viral load testing and retrospective viral
load testing is used to determine the trial’s viro-
logical outcomes.
When ODYSSEY was planned it was assumed that
DTG dosing within the trial would follow recom-
mendations arising from the IMPAACT P1093
paediatric DTG dosing study. In reality, dosing infor-
mation became available slower than expected, while
recruitment to ODYSSEY was faster than expected.
In response, ODYSSEY included several nested PK
sub-studies to allow recruitment of young children
in the three lower weight bands. Pragmatic (WHO
weight band-based) paediatric dosing using minimum
formulations was assessed across the PK substudies
aiming to simplify future procurement of paediatric
formulations. Evaluation of adult DTG dosing down
to children weighing 20 kg was incorporated, with
the goal of enabling rapid access of DTG for the
Table 6 Baseline characteristics of odyssey participants ≥14 kg at randomisation (Continued)
ODYSSEY A ODYSSEY B Total
(First-line) (Second-line)
Viral load, copies/mLb
< 1000 25 (8%) 6 (2%) 31 (4%)
1000 to < 10,000 62 (20%) 122 (31%) 184 (26%)
10,000 to < 50,000 76 (24%) 151 (38%) 227 (32%)
50,000 to < 100,000 44 (14%) 44 (11%) 88 (13%)
≥100,000 101 (33%) 73 (18%) 174 (25%)
Median Log10 Viral load (IQR), copies/mLb 4.6 (3.9–5.1) 4.3 (3.8–4.8) 4.4 (3.9–5.0)
Clinical (WHO) Staging
I 127 (41%) 143 (36%) 270 (38%)
II 113 (36%) 135 (34%) 248 (35%)
III 47 (15%) 81 (21%) 128 (18%)
IV 23 (8%) 37 (9%) 60 (8%)




Median cumulative ART exposure (IQR), yearsc 5.5 (3.5–8.1)
Percentages are of non-missing values. Abbreviations: BMI Body Mass Index, ART Antiretroviral Therapy, NRTI Nucleos(t) ide reverse transcriptase inhibitors, PI
Protease Inhibitors, NNRTI Non-nucleoside reverse-transcriptase inhibitors, IQR Interquartile Range
aAssessed using World Health Organization (WHO) 2007 STATA macro package [35].
bMean of results at screening and randomisation if both are available
cExcluding any PMTCT exposure
d 1 injecting drug use; 1 possible transmission father-to-child
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majority of children and easier implementation
within LMICs national treatment programmes.
The advantages of nested PK in a larger trial
translate into faster recruitment into PK studies and
the generation of long-term safety data. Already, PK
and safety data from ODYSSEY on the use of the
adult DTG 50 mg FCT in children weighing ≥20 kg
have been incorporated into WHO dosing guidelines
[19]. WHO has predicted that this approach of con-
ducting a parallel dose finding study (IMPAACT
P1093) with a long term efficacy, safety and simpli-
fied dosing study (ODYSSEY) will likely result in ~
500,000 children that can start or switch to DTG 3
years earlier than would otherwise have been pos-
sible [36].
Recruitment of children < 14 kg will provide valu-
able efficacy and safety data in this group. This was
allowed for in a protocol amendment, with random-
isation stratified to protect the main trial. Data from
the weight-band PK sub-studies were included as part
of FDA and EMA licensing applications for TIVI
CAY™ submitted by ViiV Healthcare and GlaxoS-
mithKline; with FDA approval for paediatric DTG re-
ceived in June 2020 and EMA approval expected early
2021.
Conclusions
As identified by the WHO and the Collaborative Ini-
tiative for Pediatric HIV Education and Research
(CIPHER), we must urgently accelerate the paediatric
HIV response with evidence-based interventions to
maximize short- and long-term outcomes in children.
Through responsive and innovative design features,
the ODYSSEY trial is contributing to this global re-
search agenda, by efficiently answering multiple re-
search questions around use of DTG in paediatric
HIV care.
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Table 7 Severe who clinical stage 3 for the odyssey trial





• Persistent oral candidiasis
(after first 6–8 weeks of life)
• Symptomatic lymphoid
interstitial pneumonitis
• Chronic HIV-associated lung
disease including bronchiectasis
• Unexplained severe weight loss
(> 10% of presumed or measured
body weight)
• Persistent oral candidiasis
Reference: World Health Organization. WHO case definitions of HIV for
surveillance, and revised clinical staging and immunological classification of
HIV related disease in adults and children. Geneva: World Health
Organization; 2007
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